[Stock Feature] Pharmax, Surges 10% on Q2 Earnings Expectations... Revaluation of Aesthetic Sector Highlighted
Pharmax is surging 10% on strong Q2 earnings expectations, with the aesthetic sector being re-evaluated. Daishin Securities estimates Q2 revenue at 162.5 billion KRW and operating profit at 66.7 billion KRW, driven by increased exports to Western Europe and Southeast Asia.
Key takeaway
"[Stock Feature] Pharmax, Surges 10% on Q2 Earnings Expectations... Revaluation of Aesthetic Sector Highlighted" — BullBear's AI rates this story as a bullish (positive) signal for markets, with a market-impact score of 45 out of 100. Pharmax is surging 10% on strong Q2 earnings expectations, with the aesthetic sector being re-evaluated. Daishin Securities estimates Q2 revenue at 162.5 billion KRW and operating profit at 66.7 billion KRW, driven by increased exports to Western Europe and Southeast Asia. Reported by TokenPost on July 23, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Catch the next bull catalyst
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 53.1%.